- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hepatocellular carcinoma (HCC)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Regorafenib – July 2019
Regorafenib: Tablet 40 mg (as monohydrate); Stivarga®
Last updated
1 November 2019